TILT Biotherapeutics Ltd

We are excited to share our latest clinical research article on TILT-123 (igrelimogene litadenorepvec) hot from the press in the Journal of Experimental & Clinical Cancer Research. (https://lnkd.in/dFSRM8Nz) One of the major limitations of approved oncolytic viruses is the need for intratumoral (i.t.) injection—TILT-123 addresses this challenge with capsid modifications that enable targeted delivery through an IV route, alongside powerful immune-activating factors (TNFα and IL-2) to enhance the body’s antitumor response. Key Findings on the study of TILT-123 used intravenously: ✅ 🛟 Well-Tolerated across all three Phase I dose escalation trials (TUNIMO, TUNINTIL, and PROTA), with 52 patients treated and no dose-limiting toxicities. ✅ 🎯 Evidence of Tumor Targeting – post-treatment biopsies confirmed TILT-123 viral expression, immune cell infiltration, and immunomodulatory effects in tumors. This research is part of TILT’s effort to pioneer intravenous delivery for TILT-123, and the results form a foundational pillar for other exclusively intravenous trials. Congratulations to Elise Jirovec and all the coauthors on the publication! 🎉 We’re excited to continue advancing oncolytic virus therapies with innovative approaches to meet the challenges of cancer treatment. 💪 #cancerresearch #oncolyticviruses #biotech #immunotherapy #clinicaltrials #TILT123

TILT Biotherapeutics is at BIO Europe 2025 in Stockholm! Come visit us at Booth 160 to learn more about our innovative immunotherapy solutions. Our COO Aino Kalervo and our VP of Business Development Victor Cervera, are on-site and ready to connect with partners and discuss the future of cancer treatment. Let’s talk science, collaboration, and innovation. Looking forward to seeing you here! #BIOEurope #Immunotherapy #Biotech #CancerResearch #TILTBio

🎗️🟪October marks an important time to support the fight against cancer through the Pink Ribbon Campaign 🟪🎗️ This initiative not only raises crucial funds for cancer research and prevention but also provides vital support services to those affected by cancer. Every donation helps bring us one step closer to breakthroughs in treatment and care. Let’s come together to make a difference—whether through donations, spreading awareness, or supporting those in need. We at TILT support Finland's Cancer Foundation Pink Ribbon Campaign 2024. This year the Pink Ribbon Campaign has a focus on lung cancers. For more information (in Finnish), visit Roosa nauha 2024 - https://lnkd.in/dtqrfhiU   #RoosaNauha #CancerResearch #SupportCancerAwareness

🚀 The TILT team gets ready for ESMO'24! 🚀 Today, we announced promising new data on our flagship cancer immunotherapy, TILT-123, which will be presented at the ESMO Congress 2024 (https://lnkd.in/dAcR5y9A). The results from a Phase I clinical study (NCT04695327) demonstrate the safety and immunological effects of TILT-123 in treating advanced solid cancers using intravenous delivery. 📊 Key Highlights: ✅ Safe treatment regimen across multiple cancer types. ✅ Disease control seen in 33% of patients by RECIST1.1 and 66% using PET-based criteria. CEO Akseli Hemminki said, "This data validates the potential of TILT-123 as a fully intravenous therapy in a challenging patient population." 🔬 Learn more at #ESMO2024 and stay tuned for updates! #CancerResearch #OncolyticViruses #Immunotherapy #Biotech #ESMO #TILT123

This past week, I had the pleasure of attending the ISCT, International Society for Cell & Gene Therapy Europe meeting, where I witnessed the exciting progress and innovation blooming in the cell therapy fields. 🌱 One of the highlights was participating in the session titled "Innovations in TIL Therapy: Melanoma Trials and Beyond," chaired by Erja Kerkelä and Anna Pasetto. We had the opportunity to hear valuable updates from Özcan Met (from the CCIT at Herlev) and and Stina L Wickström (from the Karolinska Institutet in Stockholm) on their clinical trials in the TIL space—an area showing tremendous development. 🔬 Feeling inspired by the collaborative spirit and cutting-edge advancements! #CellTherapy #TILTherapy #ISCT #Innovation TILT Biotherapeutics Ltd

📢📢We’re excited to give a huge shoutout to Tesi for their incredible support and belief in our vision—not once, but twice!📢📢 Tesi, first invested in TILT in 2022, and we’re honored that they’ve chosen to recently back us again. We’re grateful to have such a forward-thinking partner on this journey developing novel cancer treatments. A special thanks to the Tesi team for featuring our story in a case article on their website (https://lnkd.in/dB4Q7-88). They’ve captured the essence of who we are and what we stand for, giving readers a glimpse into the heart of our company. We’re excited about the future and can’t wait to continue growing together! ✨🪴✨ #Healthcare #CancerTherapy #VC #DareToGrow

We are proud to announce that TILT was selected by the European Innovation Council (EIC) as one of the best companies for funding. The equity investment will be made through the EIC Fund. With the significant 2-CREATE project funding we are moving to Phase II clinical studies & towards cancer care with TILT-123. Thank you EIC Accelerator and our evaluators! This EU-level funding is vital to keep TILT Biotherapeutics competitive globally #EUeic #Biotech #Pharma #Oncology EIC Accelerator – 68 deep-tech start-ups in the latest funding round - European Commission (europa.eu)

🔬 Exciting News from Clinical Cancer Research! 🔬 We're thrilled to share an editorial comment has been published in Clinical Cancer Research (https://lnkd.in/dFTqVvuq) regarding our recent publication (https://lnkd.in/dhWKEwe3) on TILT-123 used as monotherapy in a Phase I trial! Independent experts in the field have highlighted the promising results of our study, which tested an oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 in patients with advanced solid tumors. The authors concluded that "TILT-123 seems to be a promising candidate to join the still short list of approved oncolytic viruses," underscoring the significance of our findings in advancing cancer treatment. This recognition highlights our commitment to advancing innovative therapies in oncology and bringing hope to patients facing challenging conditions. This type of research is conditional to the patients who volunteer to advance cancer treatment, a big thank you them! Also to our dedicated team and collaborators for their hard work and expertise! #ClinicalTrial #OncolyticVirotherapy #CancerResearch #InnovationInMedicine #ClinicalCancerResearch

👇We’re excited to share an article in @ONCOLife on "How Engineered Viruses Could Transform Cancer Treatment." https://lnkd.in/gu9tW4XW 🔍TILT-123 is genetically modified to specifically target and destroy #cancer cells. 💉IV administration of TILT-123 increases patient access, simplifies logistics, and targets cancer metastases more effectively. 👩⚕️Ongoing Phase 1B trials in ovarian and lung cancer in combination with pembrolizumab have the potential to redefine cancer treatment. @American Society of Clinical Oncology (ASCO), @Hüseyin Kandemir #Biotech #Pharma #Innovation #Oncology #ClinicalTrials https://lnkd.in/dTyHEfu9

Haemme reipasta tiimiläistä määräaikaiseen työhön osakkeiden hallinnan pariin elo-marraskuulle https://lnkd.in/dFGUHHSE